高级别胶质瘤患者细胞毒性化疗副作用的管理
Managing Side Effects of Cytotoxic Chemotherapy in Patients With High Grade Gliomas.
作者信息
Ha Hyerim, Lim Joo Han
机构信息
Department of Hematology and Oncology, Inha University Hospital, Inha University College of Medicine, Incheon, Korea.
出版信息
Brain Tumor Res Treat. 2022 Jul;10(3):158-163. doi: 10.14791/btrt.2022.0018.
Abstract
Cytotoxic chemotherapy has been a mainstay of cancer treatment since the 1940s. In the recent era of emergent targeted therapies and immunotherapies, many cytotoxic chemotherapy agents including temozolomide are still one of main weapons for the treatment of high grade gliomas. However, cytotoxic chemotherapy often causes side effects. Proper management of chemotherapy-induced toxicity can have a significant impact on a patient's quality of life and clinical outcomes. Many supportive care advances have transformed our ability to give full doses of chemotherapy, which is important for achieving their full efficacy. Prevention and treatment strategies have been developed for many chemotherapy-related toxicities. This review focused on managing gastrointestinal toxicity, chemotherapy-induced nausea and vomiting, and hematologic toxicities such as thrombocytopenia during cytotoxic chemotherapy treatment in high-grade brain tumors.
摘要
自20世纪40年代以来，细胞毒性化疗一直是癌症治疗的主要手段。在近期新兴的靶向治疗和免疫治疗时代，包括替莫唑胺在内的许多细胞毒性化疗药物仍是治疗高级别胶质瘤的主要武器之一。然而，细胞毒性化疗常常会引起副作用。对化疗所致毒性进行恰当管理，可对患者的生活质量和临床结局产生重大影响。许多支持性护理方面的进展改变了我们给予全剂量化疗的能力，这对于实现其全部疗效至关重要。针对许多化疗相关毒性，已经制定了预防和治疗策略。本综述聚焦于在高级别脑肿瘤的细胞毒性化疗治疗期间，对胃肠道毒性、化疗引起的恶心和呕吐以及血液学毒性（如血小板减少症）进行管理。
相似文献
1
Managing Side Effects of Cytotoxic Chemotherapy in Patients With High Grade Gliomas.高级别胶质瘤患者细胞毒性化疗副作用的管理
Brain Tumor Res Treat. 2022 Jul;10(3):158-163. doi: 10.14791/btrt.2022.0018.
2
New Advances in Supportive Care: Chemoprotective Agents as Novel Opportunities in Geriatric Oncology.支持性治疗的新进展：化学保护剂作为老年肿瘤学的新机遇。
Curr Oncol Rep. 2022 Dec;24(12):1695-1703. doi: 10.1007/s11912-022-01324-x. Epub 2022 Aug 20.
3
Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta-analysis.成人止吐药预防中度或高度致吐性化疗引起的恶心和呕吐：网状荟萃分析。
Cochrane Database Syst Rev. 2021 Nov 16;11(11):CD012775. doi: 10.1002/14651858.CD012775.pub2.
4
Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: a randomised, active-controlled, double-blind, phase 3 trial.在癌症患者中，接受中度致吐性化疗或蒽环类和环磷酰胺方案后，使用罗哌司他预防化疗引起的恶心和呕吐的安全性和疗效：一项随机、活性对照、双盲、3 期临床试验。
Lancet Oncol. 2015 Sep;16(9):1071-1078. doi: 10.1016/S1470-2045(15)00034-0. Epub 2015 Aug 10.
5
Toxicity profile of temozolomide in the treatment of 300 malignant glioma patients in Korea.替莫唑胺治疗韩国300例恶性胶质瘤患者的毒性特征
J Korean Med Sci. 2014 Jul;29(7):980-4. doi: 10.3346/jkms.2014.29.7.980. Epub 2014 Jul 11.
6
Treatments for astrocytic tumors in children: current and emerging strategies.儿童星形细胞瘤的治疗：当前与新兴策略
Paediatr Drugs. 2006;8(3):167-78. doi: 10.2165/00148581-200608030-00003.
7
[Nimotuzumab in combination with chemotherapy for patients with malignant gliomas].尼妥珠单抗联合化疗治疗恶性胶质瘤患者
Zhonghua Zhong Liu Za Zhi. 2011 Mar;33(3):232-5.
8
Phase II study to evaluate the safety and efficacy of intravenous palonosetron (PAL) in primary malignant glioma (MG) patients receiving standard radiotherapy (RT) and concomitant temozolomide (TMZ).一项II期研究，旨在评估静脉注射帕洛诺司琼（PAL）在接受标准放疗（RT）和同步替莫唑胺（TMZ）治疗的原发性恶性胶质瘤（MG）患者中的安全性和疗效。
Support Care Cancer. 2016 Oct;24(10):4365-75. doi: 10.1007/s00520-016-3276-1. Epub 2016 Jun 6.
9
Adults with newly diagnosed high-grade gliomas.新诊断为高级别胶质瘤的成年人。
Curr Treat Options Oncol. 2001 Dec;2(6):507-15. doi: 10.1007/s11864-001-0072-y.
10
The effectiveness and cost-effectiveness of acupressure for the control and management of chemotherapy-related acute and delayed nausea: Assessment of Nausea in Chemotherapy Research (ANCHoR), a randomised controlled trial. acupressure 控制和管理化疗相关急性和延迟性恶心的有效性和成本效益：化疗相关性恶心研究评估（ANCHoR），一项随机对照试验。
Health Technol Assess. 2013 Jun;17(26):1-114. doi: 10.3310/hta17260.
引用本文的文献
1
Overcoming temozolomide resistance in glioma: recent advances and mechanistic insights.克服胶质瘤中的替莫唑胺耐药性：最新进展与机制洞察
Acta Neuropathol Commun. 2025 Jun 5;13(1):126. doi: 10.1186/s40478-025-02046-4.
2
An Immune-Enhancing Injectable Hydrogel Loaded with Esketamine and DDP Promotes Painless Immunochemotherapy to Inhibit Breast Cancer Growth.载有艾司氯胺酮和 DDP 的免疫增强型可注射水凝胶促进无痛免疫化疗抑制乳腺癌生长。
Adv Healthc Mater. 2024 Nov;13(29):e2401373. doi: 10.1002/adhm.202401373. Epub 2024 Aug 9.
3
Ropivacaine-loaded hydrogels for prolonged relief of chemotherapy-induced peripheral neuropathic pain and potentiated chemotherapy.载罗哌卡因水凝胶用于缓解化疗引起的周围神经性疼痛和增强化疗效果。
J Nanobiotechnology. 2023 Dec 2;21(1):462. doi: 10.1186/s12951-023-02230-5.
4
Naturally Occurring Phytochemicals to Target Breast Cancer Cell Signaling.天然植物化学物质靶向乳腺癌细胞信号转导。
Appl Biochem Biotechnol. 2024 Jul;196(7):4644-4660. doi: 10.1007/s12010-023-04734-0. Epub 2023 Sep 29.
5
Interleukin-21 Influences Glioblastoma Course: Biological Mechanisms and Therapeutic Potential.白细胞介素-21 影响胶质母细胞瘤病程：生物学机制与治疗潜力。
Cells. 2023 Sep 15;12(18):2284. doi: 10.3390/cells12182284.
本文引用的文献
1
The Emesis Trial: Depressive Glioma Patients Are More Affected by Chemotherapy-Induced Nausea and Vomiting.呕吐试验：抑郁型胶质瘤患者受化疗引起的恶心和呕吐影响更大。
Front Neurol. 2022 Feb 15;13:773265. doi: 10.3389/fneur.2022.773265. eCollection 2022.
2
Avatrombopag for chemotherapy-induced thrombocytopenia in patients with non-haematological malignancies: an international, randomised, double-blind, placebo-controlled, phase 3 trial.阿伐曲泊帕治疗非血液系统恶性肿瘤患者化疗引起的血小板减少症：一项国际、随机、双盲、安慰剂对照、3 期临床试验。
Lancet Haematol. 2022 Mar;9(3):e179-e189. doi: 10.1016/S2352-3026(22)00001-1.
3
Thrombopoietin receptor agonist in chemotherapy-induced thrombocytopenia.血小板生成素受体激动剂用于化疗所致血小板减少症
Lancet Haematol. 2022 Mar;9(3):e168-e169. doi: 10.1016/S2352-3026(22)00030-8.
4
Clinical Updates in Nausea and Vomiting.恶心和呕吐的临床最新进展。
Semin Oncol Nurs. 2022 Feb;38(1):151249. doi: 10.1016/j.soncn.2022.151249. Epub 2022 Feb 24.
5
Immune Thrombocytopenia Treatment.免疫性血小板减少症的治疗
N Engl J Med. 2021 Sep 2;385(10):948-950. doi: 10.1056/NEJMe2110953.
6
The thrombopoietin receptor: revisiting the master regulator of platelet production.血小板生成素受体：重新审视血小板生成的主调控因子。
Platelets. 2021 Aug 18;32(6):770-778. doi: 10.1080/09537104.2021.1925102. Epub 2021 Jun 7.
7
Antiemetics: ASCO Guideline Update.止吐药：ASCO 指南更新。
J Clin Oncol. 2020 Aug 20;38(24):2782-2797. doi: 10.1200/JCO.20.01296. Epub 2020 Jul 13.
8
Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions.成人脑胶质母细胞瘤：神经肿瘤学会（SNO）和欧洲神经肿瘤学会（EANO）关于当前管理和未来方向的共识综述。
Neuro Oncol. 2020 Aug 17;22(8):1073-1113. doi: 10.1093/neuonc/noaa106.
9
Romiplostim for temozolomide-induced thrombocytopenia in glioblastoma: The PLATUM trial.罗米司亭治疗替莫唑胺诱导的胶质母细胞瘤血小板减少症：PLATUM 试验。
Neurology. 2019 Nov 5;93(19):e1799-e1806. doi: 10.1212/WNL.0000000000008440. Epub 2019 Oct 4.
10
Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide.随机、开放标签的 II 期临床试验：与单用昂丹司琼相比，在接受辅助替莫唑胺治疗的脑胶质瘤患者中，5 天阿瑞匹坦联合昂丹司琼预防化疗引起的恶心呕吐（CINV）。
Support Care Cancer. 2020 May;28(5):2229-2238. doi: 10.1007/s00520-019-05039-x. Epub 2019 Aug 22.
Zotero 插件